Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.
Investing News Network on MSN23h
What is In-Licensing?When it comes to investing in pharmaceutical companies, looking at pipelines and research and development prospects is ...
Protein complex in bacterial cell membrane acts like a rotary motor to recruit DNA-degrading enzymes to defend against phage ...
Gilead beat consensus estimates in Q4 with $7.6 billion in revenue, driven largely by its HIV drug Biktarvy and CAR T therapies Trodelvy and Yescarta.
Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...
The overall market of herpes simplex is expected to boost with the expected launch of emerging therapy, increased awareness, and extensive research in the forecast period (2025-2034). LAS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback